Leerink Raises Genmab (GMAB) Price Target, Keeps Outperform Rating
The updated data showed positive results and supports the company’s aim to start a Phase 111 trial later this year.
Genmab A/S (GMAB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Orbis Investment Management William B. Gray | 5,710,741 | $111,816,309 | +103% | 0.64% |
| 2. | Citadel Investment Group Ken Griffin | 4,426,654 | $86,673,885 | +44% | 0.02% |
| 3. | Renaissance Technologies Jim Simons | 2,262,350 | $44,296,813 | +18% | 0.07% |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 2,181,510 | $42,713,967 | +95% | 0.05% |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 1,973,700 | $38,645,046 | +20% | 0.09% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,725,158 | $288,318,594 | 0.1% | |
| 2. | 3,517,852 | $68,879,539 | 0% | |
| 3. | 2,880,826 | $56,437,844 | 0.43% | |
| 4. | 2,838,928 | $55,586,245 | 0% | |
| 5. | 1,899,766 | $37,197,418 | 0.08% |
News See All
Genmab A/S (GMAB) Reports 50% Response Rate With Rina-S in Advanced Endometrial Cancer
Results from the Phase 1/2 RAINFOL-01 trial, presented at the 2025 ASCO Annual Meeting, show that Rina-S 100 mg/m² administered every three weeks achieved a confirmed objective response rate (ORR) of...
Genmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025
Genmab A/S (NASDAQ:GMAB) announced that it will present pivotal new research from its late-stage oncology portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30...
13 Most Profitable Growth Stocks to Buy Now
The growth factor in investing refers to companies that grow their revenue and earnings at rates significantly above the market.
8 Most Undervalued Healthcare Stocks to Buy According to Analysts
Healthcare prices and expenditures have been rising in the United States.
7 Most Profitable Biotech Stocks To Buy Right Now
With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction.
Genmab A/S (GMAB): A Bull Case Theory
We came across a bullish thesis on Genmab A/S (GMAB) on Substack by Oliver | MMMT Wealth. In this article, we will summarize the bulls’ thesis on GMAB.
10 Cash-Rich Undervalued Stocks To Invest In
Currently, big tech and high-growth stocks dominate the stock market, making up a much larger share of the broader market than they have historically.
15 Stocks That Will Go to The Moon According to Analysts
While stocks initially fell based on worries regarding Trump tariffs on America’s major trading partners, major indexes recovered from their initial losses as the President delayed tariffs on Mexico...
12 Best Growth Stocks to Invest In According to Analysts
Companies experiencing above-average earnings growth, which is often fueled by innovations and market expansions, are known as growth stocks.
Billionaire Hedge Funds
